JEM Research Institute

JEM Research Institute is dedicated to advancing clinical trials focused on neurological disorders, particularly Alzheimer’s disease and similar cognitive decline issues, through rigorous study management and patient recruitment. Established in 2008 in Lake Worth, US, JEM Research Institute specializes in managing clinical trials for various diseases. The company has executed one deal as of July 2020, when it was acquired by Headlands Research, Inc. , a portfolio company of KKR.

JEM Research Institute specializes in the implementation and management of clinical trials aimed at discovering new treatments for various diseases, particularly focusing on progressive cognitive decline disorders such as Alzheimer’s disease, multiple sclerosis, and Parkinson's disease. Their core service offerings include conducting clinical studies that involve rigorous oversight by board-certified physicians who supervise the entire process—from trial selection and patient recruitment to data management. The institute offers specialized trials for patients aged 50 and older, addressing the needs of those who may be experiencing memory loss or cognitive decline. Their services are utilized by patients seeking participation in clinical trials, pharmaceutical companies, and Contract Research Organizations (CROs) across North America and select regions in Europe, with particular attention to areas where there is a high prevalence of neurological disorders.

JEM Research Institute generates revenue primarily through contracts with pharmaceutical companies and CROs that seek to conduct clinical trials. These transactions typically involve B2B partnerships where clients engage the institute to manage trials in exchange for funding based on the scope of services provided. The revenue structure reflects payments for patient enrollment, data collection, and analysis services, which are critical in advancing drug development efforts. The institute's diverse offerings, including flagship studies related to Alzheimer’s treatment and prevention, position it as a vital partner in the clinical research landscape.

Pricing plans vary based on trial complexity and duration, with structured agreements outlining financial commitments for each phase of the clinical research process. Following its acquisition in July 2020, JEM Research Institute plans to leverage recent funding to enhance its clinical trial capabilities and expand into new markets within Europe. The institute is focusing on developing new comprehensive trial programs aimed at further understanding and treating Alzheimer’s disease and similar disorders. Future initiatives are set to be implemented in the upcoming years as they seek to engage more patients and pharmaceutical partners.